BridgeBio Pharma 和 Kyowa Kirin 合作在日本开发和商业化用于治疗骨骼发育不良的 infigratinib，BridgeBio 获得了 1 亿美元的预付款和特许权使用费。 BridgeBio Pharma and Kyowa Kirin partner for infigratinib development and commercialization in Japan for skeletal dysplasias, with BridgeBio receiving $100M upfront and royalties.
BridgeBio Pharma 和 Kyowa Kirin 合作在日本开发和商业化 infigratinib，用于治疗骨骼发育不良，包括软骨发育不全、软骨发育不全及相关病症。 BridgeBio Pharma and Kyowa Kirin have partnered for the development and commercialization of infigratinib for skeletal dysplasias, including achondroplasia, hypochondroplasia, and related conditions, in Japan. 作为独家权利的交换，BridgeBio 将获得 1 亿美元的预付款以及高达 20% 的 infigratinib 在日本销售的特许权使用费。 In exchange for the exclusive rights, BridgeBio will receive a $100 million upfront payment and up to high-twenties percent royalties on infigratinib sales in Japan. 虽然这笔交易不涉及 BridgeBio 的 acrodymidis 药物，但 Kyowa Kirin 也无法在日本获得该药物。 While this deal does not involve BridgeBio's acrodymidis drug, Kyowa Kirin will not have access to this drug in Japan either.